<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777476</url>
  </required_header>
  <id_info>
    <org_study_id>CL-010</org_study_id>
    <nct_id>NCT02777476</nct_id>
  </id_info>
  <brief_title>Clinical Performance of B-Lite® Light Weight Breast Implant</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>G&amp;G Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G&amp;G Biotechnology Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-marketing study for B-Lite® implants that carry the EC certificate for&#xD;
      marketing in Europe and AMAR certificate for marketing in Israel. To date, thousands of&#xD;
      implants have already been implanted in women. The study is open for primary augmentation&#xD;
      patients only. All surgeries will be performed as per standard practice at the given study&#xD;
      site. No parallel surgical procedures will be performed at the same session.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in breast size measurements</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in bra size measurements</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Implants</condition>
  <arm_group>
    <arm_group_label>procedure with B-Lite® Light Weight Breast Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B-Lite- Light Weight Breast Implants</intervention_name>
    <arm_group_label>procedure with B-Lite® Light Weight Breast Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetic women between the ages of 18 and 60 seeking primary breast augmentation&#xD;
&#xD;
          -  Patient is eligible to undergo MRI (i.e., no implanted metal or metal devices, no&#xD;
             history of severe claustrophobia)&#xD;
&#xD;
          -  Patient provides signed informed consent&#xD;
&#xD;
          -  Patient agrees to comply with the study protocol and complete all required follow up&#xD;
             visits, including to undergo MRI&#xD;
&#xD;
          -  Patient agrees to return the device to the Sponsor should the implant have to be&#xD;
             explanted&#xD;
&#xD;
          -  The patient has realistic expectations of surgical results after discussion with&#xD;
             investigator and is an acceptable candidate for breast augmentation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active infection anywhere in their body&#xD;
&#xD;
          -  Patient is pregnant or nursing at the time of recruitment, or has been in the 6 months&#xD;
             preceding recruitment date, or not willing to use reliable means of contraception&#xD;
             during the first year after surgery&#xD;
&#xD;
          -  Patient was implanted with any silicone implant other than breast implants (e.g.,&#xD;
             silicone artificial joints or facial implants)&#xD;
&#xD;
          -  Patient breast tissue is clinically incompatible for the procedure (e.g., tissue&#xD;
             damage resulting from radiation, insufficient tissue coverage or compromised&#xD;
             vascularity)&#xD;
&#xD;
          -  Patient has a condition, or is under treatment for any condition, which, in the&#xD;
             opinion of the investigator and/or consulting physician(s), may constitute an&#xD;
             unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems, possible&#xD;
             allergies and/or extraordinary immune response to implant)&#xD;
&#xD;
          -  The patient has a history of mental instability and/or history of pharmaceutical&#xD;
             psychiatric treatment&#xD;
&#xD;
          -  Patient unable to understand the scope of the study and/or surgery&#xD;
&#xD;
          -  The patient has any disease, including uncontrolled diabetes (e.g., HbA1c &gt; 8%), that&#xD;
             is clinically known to impact wound healing ability&#xD;
&#xD;
          -  Patient has existing costal injuries&#xD;
&#xD;
          -  Patient has abscesses, malignant tumors (cancer or recurrent metastases), clinically&#xD;
             relevant cysts or advanced fibrotic disease or patient with BIRAD ≥3&#xD;
&#xD;
          -  Are not willing to undergo further surgery for revision, if medically required&#xD;
&#xD;
          -  The patient has a confirmed rheumatic disease or syndrome (e.g., SLE, Sjogren's&#xD;
             syndrome, scleroderma, polymyositis or any connective tissue disorder, rheumatoid&#xD;
             arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any&#xD;
             other inflammatory arthritis, fibromyalgia or chronic fatigue syndrome)&#xD;
&#xD;
          -  The patient has a severe breast and upper trunk deformity&#xD;
&#xD;
          -  The patient participated in an investigational trial within 90 days of enrollment&#xD;
&#xD;
          -  The patient has undergone an invasive medical procedure within 90 days of enrollment.&#xD;
&#xD;
          -  Aesthetic addiction, drug abuse, alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmit Shmuel</last_name>
    <email>info@gg-bio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ETHIANUM</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Muller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzelia Medical Center</name>
      <address>
        <city>Herzliya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Akademikliniken</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Concept-Clinic</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>London Bridge Plastic Surgery Ltd</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

